MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.75 (247.29% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Piper JaffrayReiterated RatingOverweight$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016WedbushReiterated RatingOutperform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Credit SuisseLower Price TargetOutperform$44.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/3/2016        
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.41)($0.41)($0.41)
Q4 20161($0.46)($0.46)($0.46)
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.48)($0.48)($0.48)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.52)($0.52)($0.52)
(Data provided by Zacks Investment Research)
Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
DateHeadline
06/28/16 02:38 PMSmall Cap New Lows: Aimmune Therapeutics. (NASDAQ:AIMT), Waddell & Reed Financial, Inc. (NYSE:WDR ... - KC Register
06/27/16 07:09 AMNext Weeks Broker Price Targets For Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Fiscal Standard
06/24/16 02:23 PMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Updated Price Targets - FTSE News
06/24/16 02:23 PMAimmune Therapeutics, Inc. (AIMT) Reached a 52-Week Low - Finance Daily
06/21/16 03:06 PMAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events -
06/21/16 07:09 AMAimmune Therapeutics (AIMT) Names Daniel Adelman M.D. as Chief Medical Officer - StreetInsider.com
06/21/16 06:19 AMAimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer - [at noodls] - - New CMO Is a Seasoned Clinical Development Leader and Food Allergy and Immunology Expert - BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical ...
06/20/16 08:53 AMAnalyst Views For The Week Ahead: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Fiscal Standard
06/16/16 02:23 PMAimmune Therapeutics, Inc. (AIMT) Trades at 52-Week Low - Finance Daily
06/13/16 03:00 PMAimmune Therapeutics Inc Management Conference Call on Late-Breaker Presentation at the EAACI scheduled for 4:00 pm ET today -
06/13/16 02:23 PMAimmune Therapeutics (AIMT) Announces New Data on AR101 Phase 2; Low-Dose Regimen Supported - StreetInsider.com
06/13/16 10:00 AMAimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy - [Business Wire] - Aimmune Therapeutics, Inc. , a biopharmaceutical company developing CODIT™ treatments for life-threatening food allergies, today announced that new Phase 2 extended maintenance therapy data from Aimmune’s lead product, AR101 for peanut allergy, showed that the safety and tolerability profile improved with continued treatment, particularly in a low-dose extended maintenance regimen.
06/10/16 04:18 PMLifeSci Capital Initiates Coverage of Aimmune Therapeutics - [Accesswire] - Developing the Oral Immunotherapy AR101 for Desensitization of Peanut Allergies; Report Available here: http://www.lifescicapital.com/equity-research/aimmune/ NEW YORK, NY / ACCESSWIRE / June 10, 2016 ...
06/07/16 10:47 AMAimmune Therapeutics (AIMT) Will Make AR101 Late- Breaker Presentation at EAACI Congress - StreetInsider.com
06/07/16 07:18 AMAimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 - [at noodls] - - Dr. Rima Rachid Will Present Data on the Safety and Tolerability of AR101 for Peanut Allergy after More than One Year of Treatment - - Management Will Host Conference Call on Monday, June 13, 2016, at ...
06/03/16 02:25 PMAimmune Therapeutics Inc (AIMT) Stock Price Down 6.3% Following Insider Selling - Let Me Know About This
06/02/16 08:21 PM240000 Shares of Stock are sold by Insider Selling: Aimmune Therapeutics Inc (AIMT) Major Shareholder - Let Me Know About This - 240000 Shares of Stock are sold by Insider Selling: Aimmune Therapeutics Inc (AIMT) Major ShareholderLet Me Know About ThisAimmune Therapeutics logo Aimmune Therapeutics Inc (NASDAQ:AIMT) major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm's stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a ...Analyst Review: Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Risers & FallersWere Analysts Bullish Aimmune Therapeutics Inc (NASDAQ:AIMT) This Week?The Postall 4 news articles »
06/02/16 11:01 AMPrima Biomed (NASDAQ:PBMD) Went Down -0.93%: Aimmune Therapeutics (NASDAQ:AIMT), Old Republic ... - KC Register - Prima Biomed (NASDAQ:PBMD) Went Down -0.93%: Aimmune Therapeutics (NASDAQ:AIMT), Old Republic ...KC RegisterAimmune Therapeutics, Inc. (NASDAQ:AIMT) announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief Executive Officer of Aimmune, will present a company overview at two upcoming investor conferences in June as: Goldman Sachs 37th Annual Global ...and more »
06/01/16 04:04 PMAimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 04:02 PMAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events -
05/31/16 07:22 AMAimmune Therapeutics to Present at Upcoming June Investor Conferences - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--May 31, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for ...
05/28/16 12:00 PMHC Stocks Assessment: Aimmune Therapeutics (AIMT), Mazor Robotics (MZOR) - share market updates (press release) - HC Stocks Assessment: Aimmune Therapeutics (AIMT), Mazor Robotics (MZOR)share market updates (press release)Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) ended Wednesday session in green amid volatile trading. The shares closed up +1.07 points or 7.47% at $15.40 with 285,035.00 shares getting traded. Post opening the session at $14.35, the shares hit ...and more »
05/27/16 08:14 AMCan The Uptrend Continue for Aimmune Therapeutics (AIMT)? -
05/26/16 12:06 PMAimmune Therapeutics Inc Formed a Wedge Down Chart Pattern, Could Be One of The Worst Performers Going Forward - Wall Street Hints and News - Aimmune Therapeutics Inc Formed a Wedge Down Chart Pattern, Could Be One of The Worst Performers Going ForwardWall Street Hints and NewsThe stock of Aimmune Therapeutics Inc (AIMT) formed a down wedge with $14.63 target or 5.00% below today's $15.40 share price. The 7 months wedge indicates high risk for the $656.57 million company. If the $14.63 price target is reached, the company ...
05/23/16 12:28 PMRevenue Update on Aimmune Therapeutics Inc(NASDAQ:AIMT) - Trade Calls - Revenue Update on Aimmune Therapeutics Inc(NASDAQ:AIMT)Trade CallsAimmune Therapeutics Inc(NASDAQ:AIMT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 16, 2016. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.40. In a different note, ...and more »
05/16/16 03:22 PMAimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for ...
05/16/16 03:21 PMAimmune Therapeutics reports 1Q loss -
05/16/16 03:19 PM4:19 pm Aimmune Therapeutics reports Q1 results, provides clinical update -
05/16/16 12:11 PMDoes This Provide a Reason to Sell Aimmune Therapeutics Inc? The Stock Has Formed Bearish Wedge Down - Wall Street Hints and News - Does This Provide a Reason to Sell Aimmune Therapeutics Inc? The Stock Has Formed Bearish Wedge DownWall Street Hints and NewsThe stock of Aimmune Therapeutics Inc (AIMT) formed a down wedge with $12.90 target or 9.00% below today's $14.18 share price. The 5 months wedge indicates high risk for the $614.62 million company. If the $12.90 price target is reached, the company ...and more »
05/15/16 11:51 AMNext Weeks Broker Price Targets For Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Share Trading News - Next Weeks Broker Price Targets For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Share Trading News03/07/2016 – Aimmune Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 35 price target on the stock. 02/29/2016 – Wedbush began new coverage on Aimmune Therapeutics, Inc. giving the company a ...and more »
05/10/16 12:06 PMIs Aimmune Therapeutics Inc's Fuel For Real? The Stock Just Increased Again - B.O.D.Y Confidential - Is Aimmune Therapeutics Inc's Fuel For Real? The Stock Just Increased AgainB.O.D.Y ConfidentialThe stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) is a huge mover today! The stock increased 5.90% or $0.77 during the last trading session, hitting $13.83. Aimmune Therapeutics Inc (NASDAQ:AIMT) has declined 34.64% since October 2, 2015 and is ...
05/07/16 11:37 AMAimmune Therapeutics, Inc. (AIMT) Position Down in Latest Report from Tiaa Cref Investment Management LLC Last ... - Finance Daily - Aimmune Therapeutics, Inc. (AIMT) Position Down in Latest Report from Tiaa Cref Investment Management LLC Last ...Finance DailyTiaa Cref Investment Management LLC says it decreased its stake in Aimmune Therapeutics, Inc. stock by 33.9% in its quarterly SEC filing. Its investment was worth $455,000 a decrease of 51.4% according to the filing. Here are a few additional firms who ...and more »
05/04/16 11:33 AMHot Stocks: Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Dick's ... - KC Register - Hot Stocks: Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Dick's ...KC RegisterAimmune Therapeutics Inc (NASDAQ:AIMT)'s stock had its “overweight” rating reissued by Piper Jaffray. They currently have a $38.00 target price on the stock. Piper Jaffray's price objective indicates a potential upside of 183.58% from the stock's ...
05/04/16 07:20 AMAimmune Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--May 4, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for ...
04/29/16 11:41 AMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Short Interest Decreased By 22.71% - B.O.D.Y Confidential - Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Short Interest Decreased By 22.71%B.O.D.Y ConfidentialThe short interest to Aimmune Therapeutics Incorporated's float is 9.02%. The stock decreased 2.92% or $0.41 during the last trading session, hitting $13.65. Aimmune Therapeutics Inc (NASDAQ:AIMT) has declined 44.60% since September 23, 2015 and is ...and more »
04/28/16 11:39 AMAnalysts Forecast 10% Upside For The Holdings of RSCO - Three of RSCO's underlying holdings with notable upside to their analyst target prices are VirnetX Holding Corp (VHC), Aimmune Therapeutics Inc (AIMT), and Advaxis, Inc. (ADXS). Although VHC has traded at a recent price of $4.75/share, the average analyst ...
04/26/16 12:31 PMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorts Decreased by 2.11% After Short Covering - B.O.D.Y Confidential - Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorts Decreased by 2.11% After Short CoveringB.O.D.Y ConfidentialThe short interest to Aimmune Therapeutics Incorporated's float is 11.67%. The stock decreased 0.35% or $0.05 on April 22, hitting $14.08. Aimmune Therapeutics Inc (NASDAQ:AIMT) has declined 42.15% since September 17, 2015 and is downtrending.and more »
04/15/16 11:57 AMBroker Roundup For Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Share Trading News - Broker Roundup For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Share Trading News08/31/2015 – Bank of America Merrill Lynch began new coverage on Aimmune Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 36 price target on the stock. The share price of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) was down ...Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorts Decreased by 2.11% After Short CoveringRiversideGazette.comall 3 news articles »
04/13/16 11:45 AMPiper Jaffray Reiterates “Overweight” Rating for Aimmune Therapeutics Inc (AIMT) - Washington News Wire - Washington News WirePiper Jaffray Reiterates “Overweight” Rating for Aimmune Therapeutics Inc (AIMT)Washington News WireAimmune Therapeutics logo Aimmune Therapeutics Inc (NASDAQ:AIMT)'s stock had its “overweight” rating reiterated by equities research analysts at Piper Jaffray in a report issued on Tuesday, Marketbeat.com reports. They currently have a $38.00 target ...Aimmune Therapeutics Inc (AIMT) Given Overweight Rating at Piper JaffrayMas Market NewsPiper Jaffray Reiterates "Overweight" Rating for Aimmune Therapeutics Inc (AIMT)Web Breaking Newsall 3 news articles »
04/12/16 11:28 AMNew Analyst Ratings On Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Risers & Fallers - New Analyst Ratings On Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT). The latest broker reports which are currently outstanding on Monday 11th of April state 2 analysts have a rating of “strong buy”, ...
04/12/16 11:28 AMWere Analysts Bullish Aimmune Therapeutics Inc (NASDAQ:AIMT) This Week? - Clinton Financial - Were Analysts Bullish Aimmune Therapeutics Inc (NASDAQ:AIMT) This Week?Clinton FinancialOut of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Aimmune Therapeutics was the topic in 4 analyst reports since August 31, 2015 according to StockzIntelligence Inc.Could Aimmune Therapeutics Inc Recover After Today's Huge Decline?Stock CallerAimmune Therapeutics Reports Promising Phase 2 Data on Peanut Allergy Treatment AR101 – Shares Off 5 ...Sonoran Weekly Reviewall 4 news articles »
04/11/16 12:00 PMAimmune Therapeutics (AIMT) Announces Presentation of AR101 Phase 2, Biomarker Data at FARE Retreat - StreetInsider.com - Aimmune Therapeutics (AIMT) Announces Presentation of AR101 Phase 2, Biomarker Data at FARE RetreatStreetInsider.comAimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, announced that the company's CEO, Stephen Dilly, M.B.B.S., ...and more »
04/11/16 12:00 PMAimmune Therapeutics Reports Discussed Phase 2 Data on AR101 for Treatment of Peanut Allergy at FARE Research Retreat - Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that the company's CEO, Stephen Dilly, M.B.B.S ...
04/11/16 07:20 AMAimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101 - [at noodls] - - Aimmune Discussed Phase 2 Data, Including Peanut-Specific IgE Values, at FARE Research Retreat - BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical ...
04/09/16 11:26 AMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Latest Broker Views - Risers & Fallers - Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT). According to the latest broker reports outstanding on Friday 8th of April, 2 analysts have a rating of “strong buy”, 2 ...and more »
04/05/16 08:31 AMAimmune Therapeutics Appoints Douglas Sheehy as General Counsel and Secretary - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 5, 2016-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments ...
03/29/16 11:06 AMTrending Tickers: Pulmatrix, Inc. (NASDAQ:PULM), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Ballard Power ... - KC Register - Trending Tickers: Pulmatrix, Inc. (NASDAQ:PULM), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Ballard Power ...KC RegisterTLP Group LLC acquired a new stake in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,781,259 shares of the company's stock, ...
03/28/16 11:22 AMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming Week - Share Trading News - Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT). The latest reports which are currently in issue on Monday 28th of March state 2 analysts have a rating of “strong buy”, 2 ...Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Short Interest Decreased By 5.04%RiversideGazette.comHow Analysts Feel About Aimmune Therapeutics Inc (NASDAQ:AIMT)?Clinton Financialall 3 news articles »
03/27/16 10:43 AMHow Analysts Feel About Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Clinton Financial - How Analysts Feel About Aimmune Therapeutics Inc (NASDAQ:AIMT)?Clinton FinancialOut of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Aimmune Therapeutics was the topic in 4 analyst reports since August 31, 2015 according to StockzIntelligence Inc.and more »
03/26/16 11:14 AMAnalysts Predict 11% Upside For The Holdings of IWV - ... IWV's underlying holdings with notable upside to their analyst target prices are Proteon Therapeutics Inc (PRTO), Aimmune Therapeutics Inc (AIMT), and Ocwen Financial Corp. (OCN). Although PRTO has traded at a recent price of $6.92/share, the average ...
About Aimmune Therapeutics

Aimmune Therapeutics logoAimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company's Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. Its lead product, AR101, which has completed a Phase II study, is designed to treat peanut allergy. The Company's AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AIMT
  • CUSIP:
Key Metrics:
  • Previous Close: $10.87
  • 50 Day Moving Average: $13.75
  • 200 Day Moving Average: $15.04
  • P/E Ratio: N/A
  • P/E Growth: 0.15
  • Market Cap: $459.22M
  • Current Quarter EPS Consensus Estimate: $-1.70 EPS
Additional Links:
Aimmune Therapeutics (NASDAQ:AIMT) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha